Clinical trials: Ulcerative Colitis, Active
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)
This study is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of single-dose TD-3504 and single dose 15N2-tofacitinib in healthy subjects and subjects with UC.
- Trial name
- NCT03103412
- Testing
- TD-3504, 15N2-tofacitinib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Active Ulcerative Colitis
Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis
This is a multicenter, randomized, double-blind, placebo-controlled phase II study.
- Trial name
- NCT03235752
- Testing
- TJ301 300mg, TJ301 600mg
- Where
- 27 sites in China, South Korea and 1 more
- Volunteers
- 91 people
- Sponsor
- I-Mab Biopharma HongKong Limited
Active Ulcerative Colitis
Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)
Efficacy of ulcerative colitis to induce remission in patients with moderate to severe active ulcerative colitis.
- Trial name
- PRIMICISTIM (NCT02748590)
- Testing
- InterStim II Neurostimulator Model 3058
- Where
- France
- Volunteers
- 8 people
- Sponsor
- Nantes University Hospital
Moderate Active Ulcerative Colitis
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis.
- Trial name
- NCT03018054
- Testing
- E6007
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- EA Pharma Co., Ltd.
Ulcerative Colitis, Active Moderate
Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) for treating patients with mild to moderate Ulcerative Colitis (UC).
- Trial name
- FMTUC (NCT02390726)
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Vermont
Mild to Moderately Active Ulcerative Colitis
Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis
Green tea consists of several components, with most research focusing on the polyphenol fraction. The polyphenol fraction(-)-epigallocatechin-3-gallate (EGCG)has been studied extensively as an anti-inflammatory agent as well as a…
- Trial name
- NCT00718094
- Testing
- Polyphenon E®
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Active Ulcerative Colitis
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)
The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID 2x 500 mg mesalazine in the treatment of patients with acute ulcerative colitis
- Trial name
- NCT01745770
- Testing
- Mesalazine - TID 1000 mg, Mesalazine - TID 2x 500 mg
- Where
- Germany
- Volunteers
- 306 people
- Sponsor
- Dr. Falk Pharma GmbH
Active Ulcerative Colitis, Remission of Ulcerative Colitis
Canadian Active & Maintenance Modified Pentasa Study
The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative…
- Trial name
- CAMMP (NCT00603733)
- Testing
- 5-ASA (5-Aminosalicylate)
- Where
- 27 sites in Canada
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis, Active Moderate
Adacolumn in Refractory UC Patients Trial
The objectives of the study are to observe and document the efficacy and safety of 5 or more Adacolumn treatments, administered once weekly over 5 or more weeks, in a specific subset of ulcerative colitis patients.
- Trial name
- ART (NCT01481142)
- Testing
- (GMA) Adsorptive Apheresis
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd
Active Ulcerative Colitis
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis
The primary objective of the study is to evaluate the clinical activity of interferon beta-1a in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT00616434
- Testing
- BG9418 (Interferon beta-1a)
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 123 people
- Sponsor
- Biogen
Active Ulcerative Colitis
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis
To demonstrate that import Mesalazine (Asacol®) is non-inferior to the reference drug, marketed Mesalazine, regarding the primary endpoint (reduction of UC-DAI score)in patients with active ulcerative colitis (UC) treated for 8…
- Trial name
- NCT01257386
- Testing
- Asacol®, Mesalazine
- Where
- China
- Volunteers
- 251 people
- Sponsor
- Tillotts Pharma AG
Moderately Active Ulcerative Colitis
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis
The purpose of this study is to verify the safety and tolerability of AG011 (genetically modified L. lactis that has been engineered to secrete human Interleukin-10), and to determine whether AG011 can successfully treat the…
- Trial name
- NCT00729872
- Testing
- AG011
- Where
- 18 sites in Belgium, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- ActoGeniX N.V.